- Home
- BRBR vs TVTX Comparison
BRBR vs TVTX Comparison
Compare BRBR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | TVTX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRBR | TVTX |
|---|---|---|
| Price | $28.06 | $29.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $45.50 | $37.21 |
| AVG Volume (30 Days) | ★ 3.7M | 3.2M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $2,316,600,000.00 | $435,826,000.00 |
| Revenue This Year | $6.92 | $120.02 |
| Revenue Next Year | $6.86 | $37.00 |
| P/E Ratio | $16.61 | ★ N/A |
| Revenue Growth | 16.05 | ★ 114.22 |
| 52 Week Low | $21.67 | $12.91 |
| 52 Week High | $80.67 | $42.13 |
Technical Indicators
Market Signals| Indicator | BRBR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 36.98 |
| Support Level | $22.98 | $26.78 |
| Resistance Level | $28.27 | $29.31 |
| Average True Range (ATR) | 1.43 | 2.37 |
| MACD | 0.63 | -0.64 |
| Stochastic Oscillator | 98.26 | 38.11 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.